Home
overview
The importance of drug delivery systems is emerging as a key to product differentiation. The availability of advanced delivery technologies is essential for commercial success. Commercial Issues in Drug Delivery aims to cover key issues, such as partnering strategies and lifecycle management and provide a platform for companies to stay abreast of the latest developments in the drug delivery industry.

This conference will address the requirements of both big pharma companies and drug delivery companies when evaluating their business models. It will also look at the commercial opportunities for drug delivery companies to manufacture their own drugs as well as the current and future market opportunities. The conference will also look at practical case studies.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Barbara Conway

Dr Barbara Conway, Lecturer, Aston University

9:10 DRUG DELIVERY: AN OVERVIEW

Lisbeth Illum

Lisbeth Illum, Director, IDentity

  • The drug delivery boom
  • Novel drug delivery technologies
  • Evaluation of the drug delivery market
  • Commercial opportunities in drug delivery
  • What will the future bring?
  • 9:40 DRUG DELIVERY – CHANGES AND TRENDS

    Dr Alessandro Martini

    Dr Alessandro Martini, New Drug Delivery Systems, Director, Pharmacia

  • The expanding drug delivery industry
  • The importance of drug delivery technologies
  • Understanding the market and its needs
  • Unique opportunities for drug delivery technologies
  • 10:20 MAPPING OUT HUMAN ABSORPTION TO MAKE AN EARLY DECISION ON DRUG DELIVERY OPTIONS

    Dr Ian Wilding

    Dr Ian Wilding, Chief Executive, Pharmaceutical Profiles

  • Biopharmaceutical complexity of current discovery candidates
  • Improving selection of the right ‘enabling technology’ or delivery route in early development
  • Drug delivery at the heart of drug development
  • Human absorption studies to provide a route map for product development
  • 11:00 Morning Coffee

    11:20 ONE STOP SHOPS VS SPECIALISED DRUG DELIVERY COMPANIES

    Dr Janet Halliday

    Dr Janet Halliday, Director, Research & Development, Controlled Therapeutics

  • Only dealing with one company: the benefits
  • Benefits for pharma companies
  • Best delivery method for the drug?
  • Drug delivery company: good for business
  • The disadvantages of one stop shops
  • The view of single technology delivery companies
  • 12:00 PARTNERING IN DRUG DELIVERY DEVICE DEVELOPMENT

    Dr Cornelis Winnips

    Dr Cornelis Winnips, Vice President, Business Development, SkyePharma

  • Keys to success in drug delivery device development
  • Advantages to considering partnering at an early stage
  • Choosing the right opportunity: commercial and technology considerations
  • Planning the process
  • 12:40 Lunch

    13:40 NON-INVASIVE PROTEIN DRUG DELIVERY

    Dr Amin Khan

    Dr Amin Khan, Lilly Research Fellow, Eli Lilly

  • Protein/peptide delivery challenges - Physicochemical - Formulation approaches - Physiological
  • Advances in protein/peptide delivery systems - Pulmonary - Oral
  • 14:20 COMMERCIALIZATION OF ABSORPTION-ENHANCED TOPICAL DRUGS

    Mel Snyder

    Mel Snyder, Vice president, Market Development, MacroChem Corporation

    15:00 CHOOSING PROTEIN DELIVERY TECHNOLOGY

    Morten Baek Jensen

    Morten Baek Jensen, Executive Assistant, Manager, Strategic Support, Protein Delivery Systems, Novo Nordisk

  • Profiling drug candidates
  • Characterisation of the delivery problem
  • Identifying protein delivery systems
  • Technical issues

    Clinical/medical issues

  • Meeting the need of the customer

    Establishing collaboration with a drug delivery company

  • Pitfalls to avoid
  • 15:40 Afternoon Tea

    16:00 PROTECTING YOUR INTELLECTUAL PROPERTY RIGHTS

    Dr Nikin Patel

    Dr Nikin Patel, Chief Executive Officer, Molecular Profiles

  • Defining your delivery system
  • Deciding whether there is an infringement
  • The power of strong expert testimony
  • Defending your intellectual property
  • 16:40 THE KEY ISSUES IN DRUG DELIVERY LICENSING AND HOW TO GET THE BALANCE RIGHT

    Urban  Paulsson

    Urban Paulsson, Attorney at Law, Head, Life Science Practice Group, Stockholm, Bird & Bird

  • Feasibility studies and resulting technology
  • Field of use and other license restrictions
  • Licensee’s exploitation efforts, what is reasonable?
  • How to determine the value added by the technology
  • How to divide rights to resulting technology
  • How to address prosecution, enforcement and defense of intellectual property - rights
  • 17:20 Chairman's Closing Remarks and Close of Day One

    17:30 DRINKS RECEPTION to be held by SMi

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Amin Khan

    Dr Amin Khan, Lilly Research Fellow, Eli Lilly

    9:10 CHALLENGES AND OPPORTUNITIES FOR PRODUCT ENHANCEMENT THROUGH DRUG DELIVERY SYSTEMS

    Dr Hing Kin Chan

    Dr Hing Kin Chan, Director, Business Development, Eurand International

  • Improving a company’s product pipeline
  • Improve marketing potential and commercialisation
  • Novel areas of providing new product lines
  • Combination of drug delivery systems to enhance market potential
  • Creating uniqueness and patient value for an individual drug
  • 9:40 COMPETITION AND THE VALUE OF DRUG DELIVERY

    Bastiaan J. de Leeuw

    Bastiaan J. de Leeuw, Associate Director Business Development, Focus Inhalation

  • The character of competition in the pharmaceuticals and drug delivery
  • The challenge to differentiate products
  • Enhancing or extending competitiveness of products
  • Understanding product application domains and competitive conditions
  • 10:20 DIFFERENTIATING THE PRODUCT IN A CROWDED MARKET

    Rick Kettinger

    Rick Kettinger, Global Business Director, Colorcon

  • Maximising equity through product imaging
  • Establishing product ‘personality’
  • Dosage form image and links with perceived efficacy
  • Improving trademark application potential
  • 11:00 Morning Coffee

    11:20 COMMERCIALISATION OF A NOVEL DRUG DELIVERY TECHNOLOGY, A LONG AND WINDING ROAD

    Lew Bender

    Lew Bender, Senior Vice President, Business Development, Emisphere Technologies

  • The six criteria for creating a commercial product using a novel oral delivery technology
  • Emisphere’s unique technology explained
  • The first oral products near the marketplace (case studies)
  • 12:00 PURE PLAY DRUG DELIVERY: INHALATION, PEGYLATION AND SUPERCRITICAL FLUIDS

    Dr Christopher Searcy

    Dr Christopher Searcy, Vice President, Corporate Development, Inhale Therapeutic Systems

  • Building a multi-platform drug delivery company
  • Anticipating the unmet needs in the drug delivery space
  • Developing new models for providing products and services to partners
  • Challenges and rewards of pioneering pulmonary systems for proteins
  • Exploiting the re-birth of an old technology: PEGylation

    Establishing a breakthrough process for particle generation: SCF

  • Creating innovative therapeutics through drug delivery
  • 12:40 Lunch

    14:00 APPLICATION OF INNOVATIVE DRUG DELIVERY TECHNOLOGIES TO ENABLE DEVELOPMENT STAGE COMPOUNDS AND MAXIMIZE PRODUCT VALUE

    Woody Bryan, Ph.D.

    Woody Bryan, Ph.D., Director of Business Development, Shire Laboratories

  • Innovative tools for assessment of barriers to oral delivery.
  • Enabling delivery of a NCE via oral bioavailability enhancement of >200%.
  • Adding value to product franchise via bioavailability enhancement of >350%.
  • Enhancement tools add enabling quality to oral controlled release.
  • Application of enhancement to create baseline for oral controlled release.
  • 14:40 AIRMAX(TM) - FIRST CLASS DELIVERY TO THE LUNG HAS STAMP OF APPROVAL

    Dr Xian-Ming Zeng

    Dr Xian-Ming Zeng, Head of Pulmonary Research & Development, UK, IVAX

  • An overview of current drug delivery systems for inhalation therapeutics
  • The criteria for an ‘ideal’ inhaler
  • Introduction to X-ACT(TM) Technology
  • The delivery of a novel multi-dose dry powder inhaler, Airmax(TM) from concept to market
  • 15:20 DRUG DELIVERY IN THE FUTURE?

    Dr Frank Armstrong

    Dr Frank Armstrong, Chief Executive Officer, Phoqus

  • The imbalance of the pharma industry
  • The opportunities for drug delivery
  • The demands of drug delivery
  • What can the future look like for drug delivery?
  • 16:00 Chairman's Closing Remarks and Close of Conference Followed by Afternoon Tea

    +

    Workshops

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.